Medically reviewed by Jamin Brahmbhatt, MD IgA nephropathy (IgAN) is a kidney condition where antibodies (immune system ...

Use of sodium–glucose cotransporter-2 (SGLT-2) inhibitors rather than metformin as first-line treatment for type 2 diabetes appears to cut the risk for heart failure hospitalization but not myocardial ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The use of SGLT2 inhibitors and GLP-1 receptor agonists ...

SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, ...

When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...

Using SGLT2 inhibitors in the first-line treatment of type 2 diabetes lowered some cardiovascular risk, a claims database study showed. The combined 12-month risk for myocardial infarction (MI), ...

Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in ...